Considering hepatitis C virus infection as a systemic disease

Area of Science:

• Hepatology and Viral Diseases
• Immunology and Systemic Manifestations

Background:

• Hepatitis C virus (HCV) infection is linked to severe liver damage and significant extrahepatic manifestations, including systemic diseases like vasculitis and cardiovascular conditions.
• These extrahepatic effects can worsen patient prognosis and complicate treatment, particularly with older interferon-alpha therapies that had limited efficacy and high toxicity.

Purpose of the Study:

• To highlight the impact of HCV-related extrahepatic manifestations on patient outcomes.
• To discuss the limitations of traditional interferon-alpha treatments for HCV.
• To emphasize the transformative role of direct-acting antiviral (DAA) agents in managing HCV and its complications.

Main Methods:

• Review of existing literature on Hepatitis C virus (HCV) infection, its hepatic and extrahepatic complications.
• Analysis of treatment outcomes with interferon-alpha-based regimens versus newer direct-acting antiviral agents.
• Evaluation of the impact of HCV eradication on systemic disease burden.

Main Results:

• HCV infection leads to diverse extrahepatic manifestations that can overshadow hepatic disease and worsen prognosis.
• Interferon-alpha treatments were often ineffective and poorly tolerated, especially in patients with comorbidities.
• Direct-acting antiviral agents have revolutionized HCV treatment, offering high cure rates and reducing hepatic and extrahepatic complications.

Conclusions:

• Eradication of HCV using direct-acting antiviral agents is crucial for improving the long-term health of patients.
• DAAs significantly decrease the burden of both hepatic and extrahepatic manifestations associated with HCV infection.
• The advent of DAAs represents a major advancement in managing the comprehensive spectrum of HCV disease.